OR WAIT null SECS
This collaboration is the first commercialization into the United States and Canadian markets for Rio Biopharmaceuticals.
Oliva Therapeutics announced on June 13, 2023 a long-term partnership with Rio Biopharmaceuticals for the exclusive North American supply and distribution rights to a multi-product portfolio. This collaboration is the first commercialization into the United States and Canadian markets for Rio Biopharmaceuticals, according to the company press release.
“Oliva Therapeutics is excited and honored to have been selected as the exclusive partner for this unique and high-value portfolio of products,” said Daniel Akeson, CEO of Oliva Therapeutics, in a press release. “The Rio Biopharmaceuticals team and EMS have developed an incredible global infrastructure with a thoughtful portfolio that offers quality and value.”
Daniel Salazar, CEO of Rio Biopharmaceuticals, added that Rio Biopharmaceuticals and the EMS Pharma organization have a tremendous history of delivering high-quality, cost-conscious pharmaceuticals throughout the world. “Entering into the North American markets represents an important step in our growth and evolution, and partnering with a family-owned company in Oliva Therapeutics ensures that our culture and values are well represented,” he said in a press release.
Source: Oliva Therapeutics